Roche, Inovio Partner on Inovio's Prostate Cancer and Hepatitis B Immunotherapy Products

Roche OTC: RHHBY) and Inovio Pharmaceuticals, Inc. (NYSE: INO ) announced today that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B. The licensed compounds are currently in preclinical development and have generated